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Objectives:	   To	   present	   a	   case	   report	   and	   perform	   a	   literature	   review,	   as	   well	   as	   estimate	  
myasthenia	  gravis	  (MG)	  incidence	  in	  a	  systemic	  lupus	  erythematosus	  (SLE)	  cohort.	  
	  
Materials	   and	   methods:	   For	   the	   literature	   review,	   we	   searched	   MEDLINE	   and	   PubMed	   for	   case	  
reports	   of	   SLE	   and	  MG.	  We	   also	   calculated	  MG	   incidence	  within	   our	   clinical	   SLE	   cohort	   (females	  
only).	   	   	  
	  
Results:	  Eleven	  articles	  met	  our	  criteria,	  providing	  13	  SLE	  patients	  who	  developed	  MG.	  The	  majority	  
were	   female	   (84.6%),	   with	   the	   average	   ages	   25.6	   and	   33.5	   years	   at	   diagnoses	   of	   SLE	   and	   MG,	  
respectively.	  In	  380	  SLE	  female	  patients	  followed	  for	  2850	  person-­‐years,	  one	  MG	  case	  occurred.	   	  
	  
Conclusion:	  MG	  in	  SLE	  is	  a	  rare	  event.	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We	   recently	   treated	   a	   patient	   with	   systemic	   lupus	   erythematosus	   (SLE)	   who	   presented	   with	  
diplopia	   and	   weakness	   suggestive	   of	   myasthenia	   gravis	   (MG),	   26	   years	   after	   SLE	   diagnosis.	   Her	  
initial	   SLE	   features	   were	   malar	   rash,	   photosensitivity,	   oral	   ulcers,	   arthritis,	   pleuritis,	   seizures,	  
lymphopenia,	   and	   anti-­‐dsDNA,	   antiphospholipid	   and	   antinuclear	   antibody	   (ANA)	   positivity.	  
Although	   the	   MG	   symptoms	   were	   characteristic	   (ptosis,	   dysphagia,	   dysphonia	   and	   muscle	  
weakness)	   and	   the	   patient	   initially	   seemed	   to	   respond	   to	   pyridostigmine	   bromide,	   the	   diagnosis	  
was	  ultimately	  rejected	  in	  the	  face	  of	  repeatedly	  negative	  acetylcholine	  receptor	  (AChR)	  antibodies	  
and	  non-­‐confirmatory	  electrodiagnostic	  studies.	  This	  prompted	  a	  systematic	   review	  and	  synthesis	  
of	  existing	  literature	  on	  the	  topic.	   	  
MG	  and	  SLE	  are	  both	  autoimmune	  diseases,	  occurring	  more	  often	  in	  women	  than	  in	  men.[1-­‐4]	  
Both	   conditions	   have	   their	   highest	   prevalence	   at	   reproductive	   age	   and	   beyond	   and	   are	  
characterised	  by	  autoantibodies	  (including	  ANA,	  which	  can	  be	  present	  in	  both).[2-­‐4]	  
MG	   is	   an	   autoimmune	   neuromuscular	   disease	   caused	   by	   the	   presence	   of	   autoantibodies	  mainly	  
directed	   against	   the	   α-­‐subunit	   of	   the	   AChR[4],	  but	   also	   muscle-­‐specific	   tyrosine	   kinase	   (MuSK).	  
[1,3,4]	  
Although	  coexistence	  of	  these	  two	  diseases	  has	  been	  documented	  in	  case	  reports	  [1-­‐4],	  the	  actual	  
incidence	  rate	  of	  MG	  in	  SLE	  has	  never	  been	  estimated.	  In	  this	  study,	  we	  perform	  a	  literature	  review	  
of	  published	  cases,	  to	  describe	  demographic	  and	  clinical	  characteristics,	  and	  present	  our	  estimate	  
of	  the	  incidence	  of	  MG	  in	  a	  clinical	  cohort	  of	  female	  SLE	  patients.	   	   	  
	  
Methods	  
A	  systematic	  literature	  search	  was	  conducted	  for	  articles	  published	  between	  1994	  and	  2013,	  using	  
MEDLINE	  and	  PubMed	  terms	  “myasthenia	  gravis”	  AND	  “lupus	  erythematosus,	  systemic”.	  The	  titles	  
and	  abstracts	  of	  the	  search	  results	  were	  reviewed.	  Articles	  in	  English,	  French,	  Spanish	  and	  Japanese	  
were	  reviewed	  and	  both	  adults	  and	  paediatric	  patients	  were	  considered.	  Articles	  were	  included	  in	  
our	   analyses	   if	   they	   reported	   a	   case	   of	   SLE	   with	   later	   onset	   of	  MG.	  We	   did	   not	   include,	   in	   our	  
literature	  review,	  cases	  of	  SLE	  that	  followed	  a	  diagnosis	  of	  MG.	   	   	  
For	   the	   cases	   retrieved	   from	   the	   literature	   review,	   we	   compiled	   descriptive	   statistics	   of	  
demographic	   (age,	   sex,	   race/ethnicity)	   and	   clinical	   characteristics	   (SLE	   duration	   and	   American	  
College	   of	   Rheumatology	   (ACR)	   criteria,	   where	   available).	   We	   then	   calculated	   the	   incidence	   of	  
confirmed	  MG	  in	  the	  female	  SLE	  cohort	  followed	  from	  2004	  to	  2013	  at	  the	  McGill	  University	  Health	  
Centre	  Lupus	  Clinic.	  Each	  patient	  attends	  a	  clinical	   research	  visit	  once	  a	  year,	  as	  well	  as	   receiving	  
interval	   care	   from	   the	   lupus	   specialists	   who	  work	   in	   the	   clinic.	   Classification	   criteria	   for	  MG	   are	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A	  literature	  search	  was	  conducted	  on	  MEDLINE	  and	  PubMed	  using	  the	  terms	  “myasthenia	  gravis”	  
AND	  “lupus	  erythematosus,	  systemic”,	  limited	  to	  the	  period	  of	  1994–2013	  and	  articles	  published	  in	  
English,	   French,	   Spanish	   or	   Japanese.	   This	   resulted	   in	   35	   articles	   from	   MEDLINE	   and	   31	   from	  
PubMed,	  but	  on	  cross-­‐reference	  there	  were	  only	  38	  unique	  articles	  obtained	  from	  these	  searches	  




The	  titles	  and	  abstracts	  of	  these	  38	  articles	  were	  screened;	  25	  met	  our	  inclusion	  criteria	  and	  were	  
retained	  for	  detailed	  review.	  The	  rejected	  papers	  focused	  only	  on	  one	  or	  the	  other	  of	  the	  diseases	  
and/or	  both	  diseases	  were	  mentioned	   in	  the	  abstract	  or	  title,	  but	  they	  did	  not	  occur	  at	  the	  same	  
time.	  After	  reviewing	  the	  25	  full	  papers	  that	  met	  our	  initial	  criteria,	  we	  retained	  only	  the	  12	  articles	  
that	   reported	  at	   least	  one	  case	  of	  MG	  developing	   in	  established	  SLE.	  One	  article	   including	  8	  such	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clinical	  factors;	  thus	  it	  was	  fully	  reviewed	  but	  not	  included	  in	  the	  analysis1.	  Consequently,	  13	  cases	  
from	  11	  articles	  were	  analysed.	   	  
The	  resulting	  statistics	  calculated	  from	  the	  13	  cases	  in	  these	  11	  articles	  are	  shown	  in	  Table	  1.	  
	  
	  
The	  mean	  age	  at	  SLE	  diagnosis	  was	  25.6±9.5	  years	  (6–39	  years),	  with	  a	  mean	  SLE	  duration	  (at	  the	  
time	  of	  MG	  diagnosis)	  of	  8.1±8.2	  years	  (a	  few	  months	  to	  30	  years).	  The	  mean	  age	  at	  which	  the	  SLE	  
patients	   developed	  MG	  was	   33.5±13.8	   years	   (12–69	   years).	   As	  we	   expected,	   the	  majority	   of	   the	  
patients	  were	   female	   (84.6%);	   1	   patient	  was	  white	   (7.7%),	   3	  were	   black	   (23.1%),	   1	  was	  Hispanic	  
(7.7%),	  4	  were	  Asian	   (30.8%)	  and	  4	  unknown	   (30.8%).	   In	   the	  11	  out	  of	  13	  patients	   for	  whom	  the	  
data	  were	  available,	  the	  distribution	  of	  ACR	  SLE	  criteria	  at	  any	  point	  up	  to	  the	  MG	  diagnosis	  was	  as	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arthritis	   (90.9%),	   serositis	   (54.5%),	   renal	   disorder	   (18.2%),	   neurological	   disorder	   (36.4%),	  
haematological	  disorder	  (72.7%),	  immunological	  disorder	  (90.9%)	  and	  ANA	  positivity	  (100.0%).	   	  
Calculation	  of	  MG	  incidence	  in	  our	  SLE	  cohort	  
From	  2004	  to	  2013,	  we	  followed	  380	  female	  patients	  with	  ACR	  criteria	  for	  SLE	  for	  an	  average	  of	  7.5	  
years	   each,	   yielding	   2850	   person-­‐years	   of	   follow-­‐up.	   During	   this	   time,	   one	   case	   of	   MG	   was	  
diagnosed.	  In	  comparison,	  the	  incidence	  rate	  of	  MG	  in	  the	  female	  general	  population	  is	  most	  often	  
quoted	  as	  3	  cases/100,000	  person-­‐years.	  
	  
Discussion	  
Myasthenia	  gravis	  and	  systemic	  lupus	  erythematosus	  are	  autoimmune	  diseases	  that,	  as	  mentioned	  
in	  the	  introduction,	  have	  some	  similarities	  in	  terms	  of	  demographics,	  although	  they	  are	  very	  distinct	  
entities.	  MG	   is	   an	   organ-­‐specific	   (neuromuscular	   junction)	   autoimmune	   disease	  with	   the	   highest	  
incidence	   in	   women	   of	   reproductive	   age	   (<40),	   while	   SLE	   is	   non-­‐organ-­‐specific	   and	   also	   often	  
involves	  women	  of	   reproductive	   age	  and	  beyond1,2,4.	   The	   literature	   contains	  descriptions	  of	   both	  
MG	  developing	  after	  SLE	  and	  vice	  versa2,3.	  Still,	  the	  development	  of	  MG	  in	  SLE	  patients	  appears	  to	  
be	  rather	  rare.	   	  
In	   this	   study,	   a	   total	   of	   13	   cases	   of	  MG	   arising	   in	   SLE	   patients	  were	   found	   through	   a	   systematic	  
literature	  review.	  Most	  cases	  in	  the	  literature	  were	  relatively	  young,	  with	  a	  mean	  SLE	  duration	  of	  8	  
years	   at	   the	   time	   of	   MG	   diagnosis,	   and	   many	   were	   non-­‐white.	   One	   article1	   suggested	   that	   SLE	  
patients	  with	  MG	  diagnoses	  seem	  to	  have	   less	   frequent	  cutaneous	  and	  renal	  manifestations	  than	  
what	  has	  been	  described	  in	  SLE	  patients	  without	  MG.	  Another	  publication	  studied	  78	  MG	  patients	  
and	  suggested	  a	  much	  higher	  prevalence	  of	  SLE	  (six	  cases,	  7.7%)	  than	  in	  the	  general	  population;	  in	  
that	  paper,	  all	  SLE	  cases	  with	  MG	  were	  female.	   	  
In	  summary,	  the	  development	  of	  MG	  in	  SLE	  is	  still	  a	  rare	  event.	  Regardless,	  in	  any	  SLE	  patients	  with	  
muscle	   weakness	   and	   characteristic	   features	   (e.g.	   ptosis,	   muscle	   fatigability)	   suggesting	   MG,	  
neurological	  evaluation,	   including	  AChR	  antibodies	  and	  electrodiagnostic	  testing,	  can	  help	  exclude	  
or	  confirm	  MG.	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